CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Abiraterone acetate +1 moredrug
Likely dose
Abiraterone acetate 250 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00485303
NCT00485303Phase 2Completed
CompareCT.gov

A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Cougar Biotechnology, Inc.·interventional·Posted Jun 12, 2007·Updated Jul 2, 2013

In Brief

A Phase 2 clinical trial evaluating Abiraterone acetate and Prednisone for Prostatic Neoplasms and Prostate Cancer. Completed, enrolled 58 participants across 14 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms, Prostate Cancer
CountriesUnited Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 12, 2007
Enrollment StartJun 1, 2007
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.1 years ago

Interventions

Abiraterone acetatedrug

Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.

Prednisonedrug

Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.